Effects of BiejiaYugan Granule on TGF-β1/Smads pathway in rats with hepatic fibrosis caused by compound factors

doi:10.12047/j.cjap.6098.2021.045

Abstract

Abstract: Objective: To investigate the therapeutic effects of Biejia Yugan Granule on hepatic fibrosis caused by compound factors in rats and its effect on TGF-β1/Smads signaling pathway. Methods: SD rats were randomly divided into blank control group, model control group, colchicine group, Biejia Yugan Granule low, medium and high dose (1.85, 3.70, 7.40 g/kg) groups (n= 8 in each group). The rat model of hepatic fibrosis was established by treating with 5% alcohol 15 ml/kg (ig) everyday and injecting with 40% carbon tetrachloride (sc) twice a week for 42 days. The effects of Biejia Yugan Granule on liver function, liver index and water content, serum hepatic fibrosis related indicators, key proteins and gene expression of TGF-β1/Smads signaling pathway in rats were observed. Results: Biejia Yugan Granule at the doses of 1.85, 3.70 and 7.40 g/kg could decrease the serum levels of ALT, AST, ALP and HA, PCⅢ, C-Ⅳ, LN significantly, reduce the water content of liver tissue leads to the decrease of liver index, regulate the liver tissue TGF-β1, Smad3 mRNA and Smad7 mRNA expressions. Conclusion: Biejia Yugan Granule has obvious effects of reducing enzyme and protecting liver and inhibiting hepatic fibrosis, and inhibiting TGF-β1/Smads signaling pathway is one of its mechanisms of anti-hepatic fibrosis.

Key words: Biejia Yugan Granule (BYG), hepatic fibrosis (HF), rat, therapeutic effect, TGF-β1/Smads signaling pathway

CLC Number:

R285.5

DING Mao-peng, WEI Ling-xia, WANG Zhi-wang, CHENG Xiao-li, PANG Ya-rong. Effects of BiejiaYugan Granule on TGF-β1/Smads pathway in rats with hepatic fibrosis caused by compound factors[J]. CJAP, 2021, 37(5): 463-467.

References

[1] 叶天士. 临证指南医案·肝风[M]. 北京: 中国中医药出版社, 2008: 62-63.
[2] 朱震亨. 中医临床必读丛书·格致余论[M]. 北京: 人民卫生出版社, 2005: 2-4.
[3] 王志旺, 程小丽, 郭玫. 育阴软肝方对复合因素致亚急性肝纤维化小鼠的影响[J]. 中药药理与临床, 2013, 29(2): 176-178.
[4] 李艳, 伊航, 蔡轶伦, 等. 黄芪总黄酮对四氯化碳诱导大鼠肝纤维化的影响[J]. 中成药, 2019, 41(7): 1710-1713.
[5] 王国泰, 李京涛, 魏海梁, 等. 姜黄素通过抑制TGF-β/smad2信号通路抑制人肝星状细胞纤维化作用研究[J]. 中国免疫学杂志, 2020, 36(4): 422-427.
[6] 谢玉宝, 萧焕明, 施梅姐, 等. 肝纤维化的中医药治疗进展[J]. 时珍国医国药, 2016, 27(3): 703-706.
[7] 陈永红, 朱正平. 朱正平论肝炎病毒的中医病因学属性及治疗切要[J]. 四川中医, 2012, 30(5): 6-7.
[8] 曹力波, 李兵, 李佐军, 等. 水飞蓟素对肝纤维化小鼠的保护作用及机制探讨[J]. 中国药理学通报, 2009, 25(6): 794-796.
[9] 邵毅英, 范玉琪, 李思葳, 等. CaSR表达在大鼠糖尿病性肝硬化损伤和纤维化发生中的作用[J]. 中国应用生理学杂志, 2020, 36(1): 1-5.
[10] 董惠娟, 郭羽轩, 王鑫, 等. 睡莲花总黄酮对CCl_4致小鼠肝纤维化的保护作用[J]. 天然产物研究与开发, 2020, 32(10): 1754-1760.
[11] 肖敏, 屈小虎, 吕聚坪, 等. 吡非尼酮对四氯化碳诱导的小鼠肝纤维化的影响[J]. 中国应用生理学杂志, 2016, 32(4): 378-382.
[12] 李军, 李锋, 朱襄明, 等. 肝弥漫性病变磁共振弥散系数及血清指标与肝纤维化临床病理分期的关联性分析[J]. 解放军医学院学报, 2019, 40(3): 266-270.
[13] 汪苍, 米瑞, 叶海, 等. 磁共振T_1 mapping对大鼠肝纤维化分期的诊断价值及与血清标志物相关性分析[J]. 临床放射学杂志, 2019, 38(1): 189-193.
[14] 王乐, 丁腾, 龚伟玲, 等. 调控TGF-β1/Smads信号通路抗肝纤维化的中药有效成分研究进展[J].中国中药杂志, 2019, 44(4): 666-674.
[15] 吴雄健, 郑虹. 丹酚酸A对肝纤维化大鼠TGF-β_1/Smad信号通路的影响[J]. 赣南医学院学报, 2019, 39(11): 1088-1092.
[16] Xu FY, Liu CW, Zhou DD, et al. TGF/SMAD pathways and its regulation in hepatic fibrosis[J]. J Histochem Cytochem, 2016, 64(3): 157-167.
[17] 赵珍东, 段启, 姚丽梅, 等. 姜黄素对肝星状细胞转化生长因子β1及受体和Ⅰ、Ⅲ型胶原mRNA表达的影响[J]. 中草药, 2012, 43(5): 957-961.